Gastroesophageal Cancer | Disease Landscape & Forecast | G7 | 2022

The gastroesophageal cancer market (including gastric, gastroesophageal junction, and esophageal cancer) is witnessing a substantial change, largely fueled by the entry of immune checkpoint inhibitor combination therapies. We expect that label expansions of Opdivo (Bristol Myers Squibb) and Keytruda (Merck & Co.), as well as approvals of other programmed death-ligand 1 (PD-L1) and programmed cell death-1 (PD-1) inhibitors, will continue to reshape the human epidermal growth factor receptor-2 (HER2)-negative gastroesophageal cancer market in the coming years. Immune checkpoint inhibitors in combination with HER2-targeted agents and chemotherapy, and the anti-HER2 antibody-drug conjugate Enhertu (Daiichi Sankyo / AstraZeneca) are poised to expand treatment options for HER2-positive patients. Other treatments are targeting niche biomarkers (e.g., claudin18.2, FGFR2b) and are set to provide novel treatment options for select gastroesophageal cancer patients. Given the intense late-phase pipeline activity, we anticipate the approval of several new therapies for gastroesophageal cancer during the forecast period.

Questions answered

  • How is gastroesophageal cancer segmented by subpopulation, and how will the recent drug approvals and label expansions to the various subpopulations impact the market?
  • What are the key current therapies in gastroesophageal cancer, and how are they positioned in the treatment algorithm?
  • Which emerging therapies are the most promising, and how will they shape the future of the gastroesophageal cancer market?
  • What are the drivers and constraints in the gastroesophageal cancer market, and how will the market evolve over the forecast period?

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement

Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Login to access report

launch Related Market Assessment Reports